Actinogen Medical (ASX:ACW) Market Cap: A$122.65 Mil (As of Jun. 25, 2026)


What is Actinogen Medical Market Cap?

Actinogen Medical ASX:ACW -4.48% Market Cap is A$122.65 Mil as of Jun. 25, 2026. The stock has 4 warning signs investors should review. Among 1,431 Biotechnology companies, Actinogen Medical ranks worse than 54.79% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Actinogen Medical's share price for the quarter that ended in Dec. 2025 was A$0.061. Actinogen Medical's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 3,186.90 Mil. Therefore, Actinogen Medical's market cap for the quarter that ended in Dec. 2025 was A$194.40 Mil.

Actinogen Medical's quarterly market cap declined from Dec. 2024 (A$78.32 Mil) to Jun. 2025 (A$73.07 Mil) but then increased from Jun. 2025 (A$73.07 Mil) to Dec. 2025 (A$194.40 Mil).

Actinogen Medical's annual market cap increased from Jun. 2023 (A$72.65 Mil) to Jun. 2024 (A$166.35 Mil) but then declined from Jun. 2024 (A$166.35 Mil) to Jun. 2025 (A$73.07 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Actinogen Medical's Enterprise Value for Today is A$116.34 Mil.


Actinogen Medical  (ASX:ACW) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Actinogen Medical Market Cap Related Terms


Actinogen Medical Market Cap Historical Data

* Premium members only.

The historical data trend for Actinogen Medical's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinogen Medical Market Cap Chart

Actinogen Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 215.87 89.78 72.65 166.35 73.07

Actinogen Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.76 166.35 78.32 73.07 194.40

ASX:ACW vs VRTX, REGN, ALNY: Market Cap Comparison

For the Biotechnology subindustry, Actinogen Medical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's Market Cap distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's Market Cap falls into.



Actinogen Medical Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Actinogen Medical's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as

Market Cap (A: Jun. 2025 )=Share Price (A: Jun. 2025 )*Shares Outstanding (EOP) (A: Jun. 2025 )
=A$0.023*3177.147
=A$73.07

Actinogen Medical's Market Cap for the quarter that ended in Dec. 2025 is calculated as

Market Cap (Q: Dec. 2025 )=Share Price (Q: Dec. 2025 )*Shares Outstanding (EOP) (Q: Dec. 2025 )
=A$0.061*3186.897
=A$194.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of A$122.65 Mil mean?
Actinogen Medical (ASX:ACW) has a Market Cap of A$122.65 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Actinogen Medical and its competitors. According to the industry distribution chart, Actinogen Medical ranks #784 out of 1431 companies in the Biotechnology industry, placing it in the top 54.8%.
Is Actinogen Medical's Market Cap too high?
Actinogen Medical's current Market Cap is A$122.65 Mil. Based on the distribution chart, Actinogen Medical ranks #784 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint.
How does Actinogen Medical's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Actinogen Medical ranks #784 out of 1431 companies for Market Cap. This places Actinogen Medical in the lower half of its industry. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Actinogen Medical and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actinogen Medical's current Market Cap is A$122.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinogen Medical stock overvalued right now?
Actinogen Medical (ASX:ACW) has a current Market Cap of A$122.65 Mil. The current Market Cap is A$122.65 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Actinogen Medical (ASX:ACW), the current Market Cap is A$122.65 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinogen Medical Business Description

Other Exchanges ATGGF:USA3AC:Germany
Address 109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.